Navigation Links
BLAST in Medical Technology

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...should not be taken to make up for any missed dose. * Numbers indicate the range of percentages in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. (+) For more detailed study information, please see full Prescribing Information. Disclaimer ...

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury

...Newswire-USNewswire/ -- Many soldiers who experienced mild head trauma or a blast exposure while serving in Iraq or Afghanistan are returning to the United S...aq or Afghanistan in 2008. All had experienced a concussion, head injury or blast exposure while deployed. Nearly 98 percent of the soldiers reported h...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... limited to 5 years. Gleevec is also indicated for patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after fai...n 4 studies among adult patients, with newly diagnosed Ph+ CML, patients in blast crisis, accelerated phase, and in the chronic phase after failure of interf...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

...percent. An additional 5 patients had bone marrow blast reductions to less than 5 percent. The median dur...overy. Three additional patients with bone marrow blast reductions are undergoing second induction cycles ...ized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lympho...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

...ymphoma/leukemia as defined by the Revised European-American Lymphoma (REAL) criteria, acute myeloid leukemia (AML), chronic myeloid leukemia (CML) in blast crisis, or high grade myelodysplastic syndrome (MDS) with >10% bone marrow involvement. Potential risk for TLS was defined as diagnosis of aggressi...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... limited to 5 years. Gleevec is also indicated for patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after fai...n 4 studies among adult patients, with newly diagnosed Ph+ CML, patients in blast crisis, accelerated phase and in the chronic phase after failure of interfe...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

... About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...r types. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...ated for the treatment of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic... in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. Fo... in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. (+...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor-risk cytogenetics in order to be eligible...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor prognosis cytogenetics in order to be eli...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...r types. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths ...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

...patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced a marked decrease in peripheral blast counts on XL228 (7.2 mg/kg) and hydroxyurea which ...of tumor lysis syndrome in a patient with lymphoid blast crisis receiving concurrent treatment with hydroxy...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...loxin of 50 mg/m2 or greater on a weekly dose schedule achieved bone marrow blast reductions to less than five percent, and five of those 13 achieved either ...er of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates that over 1...

Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury

...in injury has also been described as the signature injury of the wars in Iraq and Afghanistan. As many as 400,000 U.S. servicemen have been exposed to blast injuries and could have varying degrees of TBI. Application of HBOT to these veterans could have a significant impact on their return to work, quality...

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting

...o the study, GX15-070 demonstrated potent single agent activity against ALL blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxi...l death process of apoptosis. In this study, researchers obtained leukemia blast cells from five infants and one child with primary ALL. The blasts were exp...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...ents was 12.6 months, the median duration of response was 8.8 months, and 1- and 2-year survival rates were 51% and 26%, respectively. Regardless of blast percentage, cytogenetics, or age, responses were observed in all risk groups. Additionally, the survival of the Dacogen treated group compared favorab...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...al hematopoietic blood elements (CRi) and one partial response (PR). Additionally, in the twice-weekly 40 mg/m2 dose cohort, one of three patients had blast reduction of more than 95 percent and that patient achieved a complete remission (CR). Several patients have gone on to receive and tolerate multiple ...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

...harmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007. Background on Mitotic Kinesin Inhibitors Since their in...
Other Tags
(Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
(Date:9/15/2014)... 2014) The so-called central dogma of molecular ... provided a simplified explanation for how genetic information ... , In reality, of course, the process is ... nearly 60 years ago by Nobel Laureate Francis ... one, there are multiple types of RNA, three ...
(Date:9/15/2014)... study indicates that lowland tapir populations may continue to ... Researchers from the Office National de la Chasse ... San Diego Zoo Global reviewed data retrieved from camera ... four years and compared this data to current harvest ... on hunting tapirs in French Guiana," said Matthias Tobler, ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2Scientists discover RNA modifications in some unexpected places 2
(Date:9/16/2014)... 16, 2014 AxoGen, Inc. ... the peripheral nerve repair market, announced that it will ... Surgery of the Hand (ASSH) 2014 Annual Meeting, taking ... Center in Boston, MA. , The event, entitled “Nerve ... repair, featuring a discussion by leading nerve repair experts ...
(Date:9/16/2014)... Grants Pass, OR (PRWEB) September 16, 2014 ... PhD, is experiencing a major extended drought crisis that ... basic survival. Grigg praises the many individuals who are ... many fresh water policy solutions overlook large portion of ... creating new, possibly worse crises.     , Grigg explained his, ...
(Date:9/16/2014)... Beverly Hills, CA (PRWEB) September 16, 2014 ... to announce the launch of ACLsurgeryLA.com , a ... various ACL injuries. As an avid sports lover ... best options for treatment and recovery from injuries to ... this opportunity to offer patients a resource dedicated specifically ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Registration is ... For The Warriors®, a 10K, 5K, and 1-mile walk/run ... race is sponsored by Local 338 RWDSU/UFCW, the Town ... begin at the Town of Babylon Town Hall in ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope For ...
(Date:9/16/2014)... Birmingham, Alabama (PRWEB) September 16, 2014 *To ... Birmingham, AL, visit Achieve Clinical Research on the web ( ... For those who qualify:, There is ... required , Compensation may be provided for ... stands, pneumonia and influenza are the eighth leading cause of ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3
Other Contents